West Pharmaceutical Services Inc.
West Pharmaceutical Services Announces Third-Quarter 2024 Results and Increases Fiscal Guidance
Summary
On October 24, 2024, West Pharmaceutical Services, Inc. announced its third-quarter 2024 financial results, showing a slight decline in net sales and adjusted diluted EPS compared to the prior year. The company reported net sales of $746.9 million and adjusted diluted EPS of $1.85. West Pharmaceutical Services also increased its full-year 2024 net sales guidance range to $2.875 billion to $2.905 billion and adjusted diluted EPS guidance range to $6.55 to $6.75. Additionally, the company declared a fourth-quarter 2024 dividend of $0.21 per share, a 5.0% increase over the previous quarter's dividend.
Profitelligence Alerts
Get alerts for WST
Be first to know when West Pharmaceutical Services Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Official SEC Documents
Advertisement